Sanofi to enhance synergy with China’s pharma market


Strong operations: The Sanofi headquarters in Paris. Sanofi has built three manufacturing sites in China – in Beijing, Hangzhou in Zhejiang province, and Shenzhen in Guangdong province. — Bloomberg

BEIJING: French pharmaceutical company Sanofi will accelerate the modernisation of its manufacturing sites and research network in China to better integrate these into its global industrial system, a senior company executive says.

The company will also reform its medical practices and share revolutionary new drug research and development and manufacturing technologies, innovative therapies and new drugs with China, to contribute more to the development of China’s pharmaceutical industry through cross-border integration, Wayne Shi, president of Sanofi Greater China, told China Daily.

Uh-oh! Daily quota reached.


Experience an ad-free unlimited reading on both web and app.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Wall Street set to bounce back as Tesla soars
Two major shareholders of Rexit face jail in Singapore for illegally obtaining personal data
Anwar: Iskandar Malaysia secures RM40.3bil committed investments from Jan-Sept 2024
DXN posts lower 2Q net profit of RM65.97mil
ViTrox remains cautiously optimistic for 4Q24 amid challenges
Allianz: Malaysia's inflation likely to trend at 2.9% in 2025
AWC wins RM9.5mil contract for Sungai Melaka immigration complex
Nestle posts RM85mil net profit in 3Q, declares 35 sen dividend
Ringgit gains vs greenback on stable inflation data
Texchem confident in sustaining performance amid positive economic outlook

Others Also Read